Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Human Papilloma Virus: early-phase trial registry
14 of 40 indexed Human Papilloma Virus trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #368 of 28,707 conditions by registered trial count.
40 US clinical trials · 14 currently recruiting · #368 of 28,707 conditions by registered trial count
Human Papilloma Virus: 40 US clinical trials tracked, 14 recruiting.
Human Papilloma Virus is the subject of 40 registered US clinical trials on ClinicalTrials.gov, 14 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is The University of Texas Medical Branch, Galveston, running 2 of these trials.
Enrollment posture brief
Registry condition human-papilloma-virus
OPEN 14 | RECR 35% | LATE 2 | EARLY 13 | RANK #368 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Diet Modification (35% recruiting · 20 trials)
Human Papilloma Virus lists 14 open slots (35% of 40 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Human Papilloma Virus on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Human Papilloma Virus is recruiting below its size-band peers.
14 of 40 indexed trials (35%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Human Papilloma Virus trials is spread across many organizations.
The University of Texas Medical Branch, Galveston accounts for 2 of 40 trials (5%). 34 distinct sponsors appear on at least one study for this condition label.
-
Typical Human Papilloma Virus enrolment sits around 155 participants.
Median target enrolment is 155 among the 40 trials that report a genuine target (sentinel values excluded). 12 of those (30%) plan for fewer than 100 participants.
-
Human Papilloma Virus research is mostly interventional.
30 interventional and 10 observational studies make up this index (75% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
40 total, page 1 of 1
Provider Recommendation and HPV Vaccination
Kaiser Permanente
NCT05365048
Prevention of Cervical Cancer Using the Genotyping Screening and Same-day Self-sampling
Atila Biosystems
NCT07232355
Educate and Improve Underserved Populations' Uptake and Completion of the HPV Vaccine
University of Colorado, Denver
NCT04611022
Multidimensional and Multimodal Profiling of Oropharyngeal Carcinoma
Stanford University
NCT05880797
Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)
National Institute of Allergy and Infectious Diseases (NIAID)
NCT05026138
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
The University of Texas Medical Branch, Galveston
NCT05672927
Evaluation of a Novel Point-of-Care Diagnostic Test for Human Papillomavirus (HPV)
M.D. Anderson Cancer Center
NCT06434337
Advancing HPV Vaccination Among HIV Positive Adults: The CHAMPS Study
Emory University
NCT05065840
A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer
Memorial Sloan Kettering Cancer Center
NCT05491512
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
University of Maryland, Baltimore
NCT06624839
PopSci CHW4CervixHealth
Thomas Jefferson University
NCT07336134
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
University of Chicago
NCT05108870
Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery
Ryan Carey
NCT06747390
Merck IIT: RRP Pembro and Lenvatinib
Yale University
NCT04645602
Men and Women Offering Understanding of Throat HPV
Johns Hopkins University
NCT03644563
GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose
The University of Texas Medical Branch, Galveston
NCT03943875
Development of a Self-collection Device for Cervical Cancer Screening
Teal Health
NCT05669911
Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old
Boston Medical Center
NCT05329961
TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck
Abramson Cancer Center at Penn Medicine
NCT03729518
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
National Cancer Institute (NCI)
NCT04708470
Impact of Financial Incentives
UNC Lineberger Comprehensive Cancer Center
NCT05744960
Impact of Standing Orders Optimization
UNC Lineberger Comprehensive Cancer Center
NCT05742386
Longitudinal Clinical Evaluation of the HPV Assay on the BD VIPER LT System With Cervical Specimens
Becton, Dickinson and Company
NCT02267876
Text Reminders to Immunize in a Managed Care Organization
University of Rochester
NCT01806714
HPV Message Testing and Social Media Campaign
Dartmouth-Hitchcock Medical Center
NCT03747302
A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin
The Center for the Biology of Chronic Disease
NCT02715752
Natural History of HPV From Infection to Neoplasia in Adolescents and Young Women
University of California, Los Angeles
NCT01366742
Human Papillomavirus (HPV) Vaccination Among Survivors of Childhood Cancer
St. Jude Children's Research Hospital
NCT01117389
High and Low Resource Interventions to Promote HPV Vaccines
Children's Mercy Hospital Kansas City
NCT03824093
PreTeenVax Evaluation
Emory University
NCT03186430
txt2protect: Using Text Messaging to Increase HPV Vaccination Among Young Sexual Minority Men
Northwestern University
NCT02994108
Study of Gardasil in Mid-Adult Males (MAM)
H. Lee Moffitt Cancer Center and Research Institute
NCT01432574
The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL)
Icahn School of Medicine at Mount Sinai
NCT02072148
Video to Promote HPV Vaccination
Children's Hospital of Philadelphia
NCT02196454
Candin Safety & Efficacy Study for the Treatment of Warts
Nielsen BioSciences
NCT01757392
Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer
MedImmune
NCT03162224
De-Escalation Therapy for Human Papillomavirus Negative Disease
University of Chicago
NCT03944915
Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy
Icahn School of Medicine at Mount Sinai
NCT01358097
Avelumab for People With Recurrent Respiratory Papillomatosis
National Cancer Institute (NCI)
NCT02859454
Intralesional HPV Vaccine for Condylomata
University of California, San Francisco
NCT05087849
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 6 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Human Papilloma Virus records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Human Papilloma Virus trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Human Papilloma Virus page
40 registered trials, 14 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 14 Human Papilloma Virus trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- The University of Texas Medical Branch, Galveston sponsors the most Human Papilloma Virus trials on record, review their full trial history before evaluating a specific study. See The University of Texas Medical Branch, Galveston's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Human Papilloma Virus condition card totals 40 registered trials; most-linked intervention Carboplatin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.